COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Chan, E. [1 ]
Li, X. [1 ]
Lau, C. [1 ]
Anand, S. [1 ]
机构：
[1] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.393
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV26
引用
收藏
页码：A866 / A867
页数：2
相关论文
共 50 条
  • [31] Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lieven Annemans
    Vincent Thijs
    Sophie Marbaix
    [J]. Clinical Drug Investigation, 2014, 34 : 753 - 753
  • [32] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Martin Krejczy
    Job Harenberg
    Svetlana Marx
    Konrad Obermann
    Lutz Frölich
    Martin Wehling
    [J]. Journal of Thrombosis and Thrombolysis, 2014, 37 : 507 - 523
  • [33] COST EFFECTIVENESS OF ORAL ANTICOAGULATION THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION PATIENTS: WARFARIN VERSUS THE NEW ORAL ANTICOAGULANTS RIVAROXABAN, DABIGATRAN AND APIXABAN
    Ortiz-Cartagena, Ismael
    Gotay, Antonio Orraca
    Acevedo, Jose
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 490 - 490
  • [34] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    [J]. CIRCULATION, 2014, 130
  • [35] COST-EFFECTIVENESS OF EDOXABAN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN HONG KONG
    Wu, D. B.
    Choon, W. Y.
    Lee, K. K.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [36] COST-EFFECTIVENESS ANALYSIS OF NEW ORAL ANTICOAGULANTS COMPARED TO WARFARIN IN THAI PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Dilokthornsakul, P.
    Nathisuwan, S.
    Krittayaphong, R.
    Chutinet, A.
    Permsuwan, U.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [37] Cost-effectiveness of non-Vitamin-K oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation
    Harenberg, J.
    Krejczy, M.
    Wehling, M.
    Obermann, K.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1107 - 1107
  • [38] COST EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A487 - A487
  • [39] Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
    Dilokthornsakul, Piyameth
    Nathisuwan, Surakit
    Krittayaphong, Rungroj
    Chutinet, Aurauma
    Permsuwan, Unchalee
    [J]. HEART LUNG AND CIRCULATION, 2020, 29 (03): : 390 - 400
  • [40] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Faye L. Norby
    Lindsay G.S. Bengtson
    Pamela L. Lutsey
    Lin Y. Chen
    Richard F. MacLehose
    Alanna M. Chamberlain
    Ian Rapson
    Alvaro Alonso
    [J]. BMC Cardiovascular Disorders, 17
12345